Drs John M. Kane and Scott W. Woods discuss clinical high-risk syndrome and schizophrenia, including assessment methods, interventions, and risk indicators for future psychosis.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984484). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://emedicine.medscape.com/article/288259-overview

Schizophrenia and Clinical High Risk https://www.ampscz.org/about/schizophrenia-chr/

PRIME Psychosis Prodrome Research Clinic https://medicine.yale.edu/psychiatry/research/programs/clinical_people/prodome/?locationId=460

Conversion to Psychosis in Adolescents and Adults: Similar Proportions, Different Predictors https://pubmed.ncbi.nlm.nih.gov/32248862/

Clinical Validity of DSM-5 Attenuated Psychosis Syndrome: Advances in Diagnosis, Prognosis, and Treatment https://pubmed.ncbi.nlm.nih.gov/31746950/

Prevalence of Individuals at Clinical High-risk of Psychosis in the General Population and Clinical Samples: Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/34827543/

Stability of Mental Disorder Prevalence Estimates Among School-aged Children and Adolescents: Findings From the Community-based Project to Learn About Youth-mental Health (PLAY-MH) and Replication-PLAY-MH (Re-PLAY-MH), 2014-2017 https://pubmed.ncbi.nlm.nih.gov/35661706/

The Clinician's Illusion https://pubmed.ncbi.nlm.nih.gov/6334503/

What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors https://pubmed.ncbi.nlm.nih.gov/31219164/

Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study https://pubmed.ncbi.nlm.nih.gov/27806157/

Accelerated Cortical Thinning Precedes and Predicts Conversion to Psychosis: The NAPLS3 Longitudinal Study of Youth at Clinical High-risk https://pubmed.ncbi.nlm.nih.gov/36434057/

Treatment Outcomes for Young People at Clinical High Risk for Psychosis: Data From a Specialized Clinic https://pubmed.ncbi.nlm.nih.gov/34309198/

Real-world Effectiveness of Antipsychotic Treatment in Psychosis Prevention in a 3-year Cohort of 517 Individuals at Clinical High Risk From the SHARP (ShangHai at Risk for Psychosis) https://pubmed.ncbi.nlm.nih.gov/32436725/

The PRIME North America Randomized Double-blind Clinical Trial of Olanzapine Versus Placebo in Patients at Risk of Being Prodromally Symptomatic for Psychosis: I. Study Rationale and Design https://pubmed.ncbi.nlm.nih.gov/12648731/

Accelerating Medicines Partnership® Program - Schizophrenia (AMP® SCZ) https://www.nimh.nih.gov/research/research-funded-by-nimh/research-initiatives/accelerating-medicines-partnershipr-program-schizophrenia-ampr-scz#:~:text=The%20Accelerating%20Medicines%20Partnership%C2%AE,multiple%20public%20and%20private%20organizations.